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Abstract
Background Cost-utility analyses are frequently con-
ducted to compare treatments for hepatitis C, which are
often associated with complex regimens and serious
adverse events. Thus, the purpose of this study was to
estimate the utility associated with treatment administra-
tion and adverse events of hepatitis C treatments.
Design Health states were drafted based on literature
review and clinician interviews. General population par-
ticipants in the UK valued the health states in time trade-
off (TTO) interviews with 10- and 1-year time horizons.
The 14 health states described hepatitis C with variations in
treatment regimen and adverse events.
Results A total of 182 participants completed interviews
(50 % female; mean age = 39.3 years). Utilities for health
states describing treatment regimens without injections
ranged from 0.80 (1 tablet) to 0.79 (7 tablets). Utilities for
health states describing oral plus injectable regimens were
0.77 (7 tablets), 0.75 (12 tablets), and 0.71 (18 tablets).
Addition of a weekly injection had a disutility of -0.02. A
requirement to take medication with fatty food had a dis-
utility of -0.04. Adverse events were associated with
substantial disutilities: mild anemia, -0.12; severe anemia,
-0.32; flu-like symptoms, -0.21; mild rash, -0.13; severe
rash, -0.48; depression, -0.47. One-year TTO scores were
similar to these 10-year values.
Conclusions Adverse events and greater treatment regi-
men complexity were associated with lower utility scores,
suggesting a perceived decrease in quality of life beyond
the impact of hepatitis C. The resulting utilities may be
used in models estimating and comparing the value of
treatments for hepatitis C.
Keywords Utility  Cost-utility  Hepatitis C 
Time trade-off  Treatment process utility 
Time horizon
Introduction
The hepatitis C virus is one of the most common blood-
borne infections worldwide [1–3]. It is estimated that up to
85 % of individuals who are infected with the hepatitis C
virus develop a chronic hepatitis C (CHC) infection [4–6],
which typically persists for an individual’s lifetime if left
untreated [3]. Although a majority of patients with CHC
are asymptomatic in early phases of the disease [7, 8], the
disease can gradually progress to serious symptomatic life-
threatening liver conditions such as cirrhosis and liver
cancer [9–12].
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A range of pharmaceutical treatments is available for
CHC, with the treatment goal of sustained virological
response (SVR) defined as no detectable hepatitis C virus
12 weeks after discontinuing therapy [13]. Current treat-
ments are administered typically for 24–48 weeks in
complex combination treatment regimens involving injec-
tions plus a substantial number of daily tablets that may
need to be administered at precise intervals throughout the
day [14–16]. CHC treatments are also frequently associated
with serious side effects, such as anemia, depression, flu-
like symptoms, and skin problems [17–20]. The complex
treatment regimens and adverse event profiles of available
treatments likely lead to non-adherence to CHC treatment
[21–24], which is likely to reduce treatment effectiveness.
However, the landscape of treatment options for CHC is
expanding with the recent development and approval of
new treatment regimens that are more tolerable, simpler to
administer than previously available regimens, and have
shorter treatment duration [25–30].
As these new treatments for CHC are introduced, it is
important to compare their cost-effectiveness to previously
available treatments in order to demonstrate their value to
clinicians, payers, and health technology assessment
agencies. Cost-effectiveness analyses focusing on CHC
treatments are often cost-utility models, which include the
preferences of individuals for various health states and
treatment-related outcomes [31–37]. In cost-utility models,
treatment outcome is quantified in terms of utilities, which
are scores representing the strength of preferences for
health states, anchored on a scale with 1 representing full
health and 0 representing dead [38, 39]. Although pub-
lished utilities are available to represent various severity
levels of hepatitis C and related complications [40–44],
little is known about the utility impact of treatment pro-
cesses and adverse events associated with treatments for
CHC. Only one study was located that examined some of
these attributes, and it focused specifically on injection
frequency and the adverse event of flu-like symptoms [45].
While results of this previous study are useful, they do not
provide insight into the utility associated with the sub-
stantial pill burden and wide range of serious adverse
events often associated with CHC treatments.
Therefore, the purpose of the current study was to
estimate the utility or disutility (i.e., reduction in utility
score) of a broad range of treatment administration attri-
butes and common adverse events associated with hepatitis
C treatments. Given that these treatments vary widely in
terms of treatment burden and adverse event profile, it may
be important to identify utilities associated with these
attributes so that they can be represented accurately in cost-
utility models comparing treatments. These treatment
attribute differences may be particularly important for
models focusing on CHC because pharmaceutical
treatments often have similar efficacy as indicated by
similar SVR rates [46, 47]. Even when two treatment
regimens have similar efficacy, the patient experience can
vary substantially due to differences in treatment process
and adverse events, and these differences should be cap-
tured in cost-utility models. To identify these utility values
in the current study, respondents were asked to rate
hypothetical health state descriptions (often called vign-
ettes) in time trade-off (TTO) interviews. This common
utility assessment method is well-suited for isolating the
impact on utility of specific treatment attributes that are
unlikely to be captured by generic preference-based
instruments such as the EQ-5D [48] or Health Utilities
Index [49].
Although utilities are most frequently used to quantify
preferences for health outcomes, there is a growing body of
research focused on ‘‘process utilities’’. These studies have
examined the utility impact of the treatment process itself
in addition to the utilities associated with specific symp-
toms, medical conditions, or treatment outcome. For
example, studies have found that utilities are influenced by
treatment modalities including surgical versus nonsurgical
management [29]; inhaled versus injected treatment [50];
oral versus injectable treatment [51, 52]; dose frequency
[51, 52]; inpatient versus outpatient treatment [53]; two
types of prenatal genetic testing [54]; early-stage cervical
cancer treatment options [55]; and specific medication
options [56]. These studies have been able to detect dif-
ferences in preference, and more convenient treatment
processes are generally associated with greater utility val-
ues. The current study adds to this developing literature on
process utilities.
Methods
Study overview
Chronic hepatitis C (CHC) health state descriptions were
drafted based on literature review and input from clini-
cians. Then, the health states were refined based on addi-
tional clinician interviews and a pilot study conducted with
general population respondents in London, UK. Finally,
health states were rated in a TTO valuation study with
general population participants in Edinburgh and London,
UK. All participants completed the TTO valuations twice,
including once with a 10-year time horizon and once with a
1-year time horizon. A 10-year time horizon was used to
maximize comparability with previously published utility
studies. Participants also rated the health states in a TTO
task with a 1-year time horizon in order to obtain prefer-
ences for health states lasting for a period of time which
more closely mirrors typical treatment duration.
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Health state development
Health state descriptions were drafted based on interviews
with clinicians and literature review. Telephone interviews
were conducted with three clinicians who specialized in
treatment of patients with hepatitis C. Two of the clinicians
were from the US, while the other was based in the UK.
Interviews were first conducted with all three clinicians to
inform health state development, with questions focusing
on patients’ typical experiences with hepatitis C, the range
of available treatment regimens, and common treatment-
related adverse events. After health states were drafted
based on clinician input, the draft health states were sent to
the three clinicians so that they could review the text and
comment on its clarity and accuracy. Minor revisions were
made based on these comments.
Literature review was conducted throughout the health
state development process to inform the clinician interview
questions and ensure that the health state descriptions were
consistent with published research. Literature searches
focused on the symptoms and impact of hepatitis C [4, 8,
10]; treatment regimens of available and experimental
pharmaceutical treatments for hepatitis C [7, 15, 25]; and
treatment-related adverse events that clinicians considered
to be most common and bothersome for patients [17, 18,
20, 57–60]. Literature was initially identified by searching
for relevant terms in MEDLINE, and additional articles
were suggested by the three clinicians who were inter-
viewed for this study.
Health states were tested in a pilot study conducted with
24 general population participants in London, UK (9
female; mean age = 26.3 years; age range = 19–45 years)
recruited via newspaper and online advertisements. Each
participant valued the states using multiple utility assess-
ment methods, including TTO with two time horizons (1-
and 10-year), standard gamble (SG), chaining approaches
(i.e., TTO and SG using an undesirable living health state
rather than dead as a lower anchor), and a path state
approach (i.e., a sequence of health states grouped into a
single life span rated with TTO). The order in which par-
ticipants completed tasks was randomized (11 completed
SG first; 8 completed TTO first). Most methods yielded
utility scores in a reasonable range with logical discrimi-
nation among health states. Based on these results, the TTO
method was selected for use in the subsequent main study
with a larger sample because it was relatively easy for
participants to understand and complete, and because it is
consistent with the methods used in many recent utility
valuation studies, including the influential measurement
and valuation of health (MVH) study that identified utilities
of EQ-5D health states [61, 62]. Participants consistently
reported that the health states were clear and easy to
understand. Some participants suggested minor revisions in
formatting and word choice, and the health states were
edited accordingly.
Results of the pilot study were presented to clinicians,
who were asked if they believed the differences among
health state utilities were a reasonable representation of
patients’ experiences. All clinicians agreed that the pilot
study results were logical. For example, the adverse event
of depression was associated with a relatively large dis-
utility, and clinicians thought this was justified given the
severity level of depression that can emerge as a side effect
of CHC treatment.
Final health states administered in TTO interviews
A total of 14 health states were administered (see Elec-
tronic Supplement Appendix A for full health state text).
All health states included the same description of hepatitis
C, including explanation of the virus, long-term risks,
indication that the condition is currently asymptomatic, and
a brief description of fear and stress that can accompany
the disease. The first four health states, labeled A–D,
included additional statements briefly describing oral-only
treatment regimens ranging from one tablet per day (A) to
seven tablets per day (D). These oral-only health states
were designed to be consistent with regimens of recently
tested and/or approved treatments [25, 27, 63].
The next four health states, E–H, described treatment
regimens including oral and injectable medication. These
health states were designed to represent the most common
treatment regimens, which include varying numbers of
orally administered tablets plus weekly interferon injec-
tions [18, 64]. Numbers of tablets in these health states
ranged from 7 to 18 per day. The health states with a
12-tablet daily regimen (F and G) were designed to rep-
resent telaprevir plus ribavirin [65, 66], while the 18-tablet
daily regimen (H) corresponds to treatment with boceprivir
plus ribavirin [67–69]. Because the requirement to take
telaprevir with fatty food may be aversive to some patients
[16, 65, 66], the telaprevir treatment regimen was presented
with (F) and without (E) this treatment attribute so that the
disutility of the fatty food requirement could be calculated.
The final six health states (I–N) described a treatment
regimen identical to health state E (seven tablets daily plus
weekly injections), but each of these six health states added
a single adverse event. Two of these health states described
mild (I) and severe (J) anemia, which is an adverse event
associated with several common CHC treatments, includ-
ing ribavirin [17], alpha interferon [17], and protease
inhibitors such as telaprevir [57, 70] and boceprevir [70].
Health state K described flu-like symptoms emerging after
weekly injections, which is common with alpha interferon
treatment [18, 71, 72]. Health states L and M described
mild and severe rashes, which have been shown to be
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related to treatment with ribavirin [18, 73] and telaprevir
[58, 65]. The rash that emerges with telaprevir can be
particularly severe, as represented in health state M [59,
65]. Finally, health state N described depression, which has
previously been reported in patients treated with alpha
interferon [19] and ribavirin [18, 60].
Participants
Participants were required to be (1) at least 18 years old;
(2) able to understand the assessment procedures; (3) able
and willing to give written informed consent; and (4)
residing in the UK. Inclusion criteria did not specify par-
ticular clinical characteristics because interviews were
intended to yield utilities that may be used in cost-utility
analyses for submission to health technology assessment
agencies such as the National Institute for Health and Care
Excellence (NICE), most of whom prefer that utilities
represent general population values [74–77].
Participants were recruited via advertisements in three
newspapers in Edinburgh, two newspapers in London, and
the website http://www.gumtree.com/. A total of 585
individuals responded to the advertisements, and 252 of
these were reached for screening. Of the 252 screened
participants, 251 were eligible, 215 were scheduled for
interviews, and 188 participants attended interviews. Of the
188 participants, 6 were unable to complete the TTO
interview procedures. Thus, a total of 182 valid interviews
were completed.
Utility interview procedures and scoring
Utilities were derived by eliciting values for the health state
descriptions in a TTO utility interview. In TTO procedures,
the duration of time spent in the health state being rated
(i.e., the time horizon) is an important component of the
task. This time horizon varies across TTO studies. The most
commonly used TTO time horizon appears to be 10 years,
which is likely favored because of its simplicity for inter-
viewers and respondents as well as because it was used in
the MVH study that elicited utilities for EQ-5D health states
[62, 78]. However, other time horizons are also frequently
used, ranging from 1 or 2 years to longer time horizons
based on each respondent’s life expectancy [79–85].
In the current study, TTO interviews were completed
with two time horizons. All participants rated the complete
set of health states twice, with a 10-year time horizon and a
1-year time horizon. The 10-year time horizon was used to
maximize comparability with previously published TTO
utility studies, including the MVH study [62, 78]. How-
ever, all health states included a description of a hepatitis C
treatment course, which typically lasts approximately
24–48 weeks [16]. Therefore, the shorter time horizon was
used so that health states would be rated in a TTO task that
more closely matches the true clinical timeframe of the
health states. To control for order effects, participants were
randomly assigned to complete either the 10- or 1-year
TTO first, followed by the other time horizon.
To introduce participants to the health state descriptions,
a ranking exercise was conducted. After each participant
ranked the health states in order of preference, health state
utilities were obtained using the TTO method. Health states
were not presented with the organized lettering system
used in current tables (i.e., A–N). Instead, health states
were numbered in a random order so that lettering/num-
bering would not provide an indication of which health
states might be more or less preferable.
For TTO ratings of each health state, participants were
offered a choice between spending a 10- or 1-year period in
the health state versus spending shorter amounts of time in
the full health state (1-year increments in the 10-year TTO;
1-month increments in the 1-year TTO). For each health
state, choices were presented in an order that alternated
between longer and shorter durations in full health (e.g.,
10, 0, 9, 1, 8, 2, 7, 3, 4, and 5 years). Each health state rated
as better than dead received a utility value on a scale with
the anchors of dead (0) and full health (1). The assigned
value was calculated based on the choice in which the
respondent is indifferent between y years/months in the
health state being evaluated and x years/months in full
health (followed by dead). The resulting utility estimate
(u) is calculated as u = x/y.
If participants indicated that a health state was worse
than dead, the interviewer altered the task so that respon-
dents were offered a choice between immediate death
(alternative 1) and a 10-year/1-year life span (alternative 2)
beginning with varying amounts of time in the health state
being rated, followed by full health for the remainder of the
time horizon. For these health states, the current study used
a bounded scoring approach, which is commonly used to
avoid highly skewed distributions for negative utilities
[86]. This scoring approach limits the utility range of
health states worse than dead to values between 0 and -1.
To compute these bounded negative utility values, the
current study used the Dolan method [78] as described by
Rowen and Brazier [39]. This method uses the formula
u = -x/t, where x is the period of time in full health, and t
is the total life span of alternative 2 in the TTO choice. In
the current study, t was 10 and 1 year, which was the
period of time in the health state being rated plus sub-
sequent years/months in full health.
Data collection and statistical analysis procedures
Interviews were conducted in private conference rooms in
London and Edinburgh in June 2013. All procedures and
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materials were approved by an independent Institutional
Review Board, and every participant provided written
informed consent before completing any study proce-
dures. All interviews were conducted by the project
manager or other trained members of the project team.
The interviews followed a standardized interview guide,
and the TTO choices were presented with the use of
booklets in which each page had an image depicting a
different TTO choice. Participants completed a brief
demographic and clinical form, followed by the TTO
utility interview described above. Statistical analyses were
completed using SAS version 9.2 (SAS Institute, Cary,
NC).
Continuous variables, including utilities and pairwise
differences between health state utilities, are summarized
in terms of means and standard deviations, and categorical
variables such as gender and racial/ethnic background are
summarized as frequencies and percentages. Demographic
characteristics of the London and Edinburgh subgroups
were compared with Chi-square analyses (for categorical
variables) and t tests (for continuous variables).
Utility differences were examined for pairs of health
states that were directly comparable to each other. The
difference between two health states that differ in only one
treatment attribute represents the disutility (i.e., decrease in
utility score) or added utility (i.e., increase in utility score)
associated with that treatment attribute. For example,
health states D and E are identical except for the addition
of a weekly injection to health state E. Therefore, the
difference between health states D and E represents the
disutility of a weekly injection in the context of treatment
for hepatitis C. In addition, pairwise comparisons between
health states were conducted using t tests to examine
whether utility differences were statistically significant.
Results
Sample description
The total sample included 182 participants with a mean age
of 39.3 years (SD = 15.1) (Table 1). The sample was
Table 1 Sample demographic
characteristics
* P values are based on t tests
for continuous variables and
Chi-square analyses for
categorical variables, comparing
the London and Edinburgh
subgroups
Demographic characteristics Edinburgh subgroup
(N = 88)
London subgroup
(N = 94)
Total sample
(N = 182)
P value*
Age (mean, SD) 41.0, 14.9 37.8, 15.3 39.3, 15.1 0.15
Gender (n, %)
Female 47 (53.4 %) 44 (46.8 %) 91 (50.0 %) 0.37
Male 41 (46.6 %) 50 (53.2 %) 91 (50.0 %)
Ethnicity (n,%)
White 83 (94.3 %) 53 (56.4 %) 136 (74.7 %) \0.0001
Mixed 2 (2.3 %) 9 (9.6 %) 11 (6.0 %)
Asian 3 (3.4 %) 11 (11.7 %) 14 (7.7 %)
Black 0 18 (19.1 %) 18 (9.9 %)
Other 0 3 (3.2 %) 3 (1.6 %)
Marital status (n, %)
Single 46 (52.3 %) 56 (59.6 %) 102 (56.0 %) 0.20
Married 30 (34.1 %) 21 (22.3 %) 51 (28.0 %)
Other 12 (13.6 %) 17 (18.1 %) 29 (15.9 %)
Employment status (n, %)
Full-time work 24 (27.3 %) 25 (26.6 %) 49 (26.9 %) 0.97
Part-time work 23 (26.1 %) 26 (27.7 %) 49 (26.9 %)
Other 41 (46.6 %) 43 (45.7 %) 84 (46.2 %)
Education level (n, %)
No formal qualifications 4 (4.5 %) 1 (1.1 %) 5 (2.7 %) 0.046
GCSE/O-levels or
equivalent
11 (12.5 %) 11 (11.7 %) 22 (12.1 %)
A-levels or equivalent 10 (11.4 %) 27 (28.7 %) 37 (20.3 %)
Vocational/work-based
qualifications
6 (6.8 %) 9 (9.6 %) 15 (8.2 %)
University degree 29 (33.0 %) 29 (30.9 %) 58 (31.9 %)
Post-graduate degree (MA,
PhD, PGCE)
21 (23.9 %) 12 (12.8 %) 33 (18.1 %)
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evenly split between men (n = 91) and women (n = 91).
The majority of participants reported ethnicity as white
(74.7 %), and more participants reported being single
(56.0 %) than married (28.0 %). Most participants reported
being employed (26.9 % full-time and 26.9 % part-time).
Half of the sample had completed a university degree
(n = 91; 50.0 %). When asked to report health conditions,
the most common responses were depression (n = 15;
8.2 %), anxiety (n = 8; 4.4 %), arthritis (n = 8; 4.4 %),
hypertension (n = 7; 3.8 %), and cancer (n = 7; 3.8 %).
One respondent reported having hepatitis C (0.05 %) and
another reported having hepatitis B (0.05 %).
There were no significant differences between the
London (n = 94) and Edinburgh (n = 88) samples in age,
gender, marital status, or employment status. However, the
Edinburgh sample had a significantly higher percentage of
white participants than the London sample (94.3 vs
56.4 %; P\ 0.001). There was also a significant difference
in education level, as the Edinburgh subgroup was more
likely to have attained a university or post-graduate degree
(P = 0.046).
Health state ranking
In the introductory ranking task, rankings ranged from 1
(most preferable health state) to 14 (least preferable health
state). On average, greater treatment regimen complexity
was associated with lower rankings, and health states with
adverse events were ranked below health states without
adverse events. Mean rankings for each of the 14 health
states were as follows (in order of most preferable to least
preferable): health state A (mean ranking = 1.02); B (1.99);
C (2.99); D (4.01); E (5.00); F (6.27); G (7.68); H (8.23); I
(9.40); L (9.85); K (10.76); J (12.02); N (12.78); M (13.01).
Health state utilities (10-year time horizon)
Health state utility scores are presented in Table 2. All 182
participants had complete utility data for the full set of 14
health states. The health states describing all-oral treatment
regimens had the highest 10-year TTO utility values,
ranging from 0.79 for seven tablets per day (health state D)
to 0.80 for one tablet per day (A). Health states with
weekly injections had lower utility values than health states
with all-oral regimens, ranging from 0.71 (H: weekly
injection ? 18 tablets per day) to 0.77 (E: weekly injec-
tion ? seven tablets per day).
All health states with adverse events (I–N) had lower
10-year TTO utility values than any of the health states
without adverse events (A–H). Among the adverse event
health states, the highest utility scores were for I (mild
anemia) and L (mild rash), which both had mean 10-year
utilities of 0.65. The lowest utility values were for health
states describing depression (health state N; utility = 0.31)
and severe rash (M; 0.30).
Health state utilities (1-year time horizon)
The mean 1-year TTO utility scores were similar to the
10-year scores, or in some cases, identical when rounded to
two decimal places (Table 2). For 13 of the 14 health
states, the 1- and 10-year scores had a utility difference of
0.02 or less. The only health state with a larger difference
between the time horizons was health state M (severe rash),
with a difference of 0.04 between the 10- and 1-year
scores.
Comparisons between pairs of health states differing
in treatment administration attributes
Difference scores were computed to identify the disutility
associated with various treatment attributes. All pairwise
difference scores between health states varying in treat-
ment administration attributes (health states A–H) are
presented in Table 3. In addition, differences between pairs
of health states that vary in only one treatment attribute are
Table 2 Time trade-off (TTO) health state utilities (N = 182)
Hepatitis C health states TTO with
10-year
time
horizon
TTO with
1-year time
horizon
Mean SD Mean SD
Health states differing by treatment regimen
A. All-oral regimen (1 tablet per day) 0.80 0.30 0.81 0.29
B. All-oral regimen (2 tablets per day) 0.80 0.30 0.81 0.29
C. All-oral regimen (3 tablets per day) 0.79 0.30 0.80 0.29
D. All-oral regimen (7 tablets per day) 0.79 0.30 0.79 0.29
E. Oral treatment (7 tablets per
day) ? weekly injection
0.77 0.30 0.77 0.30
F. Oral treatment (12 tablets per
day) ? weekly injection
0.75 0.31 0.76 0.32
G. Oral treatment (12 tablets per day
taken with fatty food) ? weekly
injection
0.71 0.35 0.72 0.35
H. Oral treatment (18 tablets per
day) ? weekly injection
0.71 0.35 0.72 0.33
Health states differing by adverse events
I. Health state E ? mild anemia 0.65 0.36 0.65 0.38
J. Health state E ? severe anemia 0.45 0.42 0.47 0.41
K. Health state E ? flu-like symptoms 0.56 0.39 0.57 0.39
L. Health state E ? mild rash 0.65 0.40 0.66 0.37
M. Health state E ? severe rash 0.30 0.50 0.34 0.47
N. Health state E ? depression 0.31 0.48 0.33 0.48
TTO scores are on a scale anchored with 0 representing dead and 1
representing full health
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examined with t tests in Table 4. Because the health state
pairs in Table 4 were identical except for a single differ-
ence in treatment regimen, any difference in utility score
represents the impact of the treatment attribute differences
on respondent preference. The 10- and 1-year analyses
followed similar patterns, and both sets of results are pre-
sented in Tables 3 and 4. The 10-year results are summa-
rized here.
In general, health states describing more complex and
burdensome treatment regimens were associated with
lower utility values. While some treatment regimen dif-
ferences had virtually no impact on utility (e.g., one tablet
vs. three tablets per day), other treatment regimen differ-
ences were associated with substantial utility differences.
For example, the difference between the least burdensome
regimens (health states A, B, and C) and most burdensome
regimens (health states G and H) was 0.09 (Table 3).
Among the all-oral treatment regimen health states (A
through D), the magnitude of utility differences was min-
imal (i.e., rounding to either 0.01 or 0.00) despite reaching
statistical significance in some cases. The addition of a
weekly injection to an otherwise identical health state (i.e.,
comparison between D and E) resulted in a statistically
significant utility difference of 0.02 (P\ 0.001). Among
regimens including weekly injections, differences in the
number of tablets were associated with statistically sig-
nificant utility differences (health states E vs. F, E vs. H,
and F vs. H; all P\ 0.001). Adding the fatty food
requirement to a 12-tablet daily regimen resulted in a sta-
tistically significant utility reduction (difference = 0.04;
P\ 0.001) (Table 4).
Comparisons between pairs of health states differing
in adverse events
The disutility of each adverse event was computed by
subtracting the utility of each adverse event health state (I
through N) from the utility of health state E (Table 5). The
adverse event health states were identical to health state E
other than the addition of the adverse event. Thus, the
utility difference between health state E and these other
health states represents the impact of each adverse event on
respondent preference. The 10- and 1-year analyses fol-
lowed similar patterns (Table 5), and the 10-year results
are summarized here.
All adverse event health state utilities were significantly
different from the utility of health state E (all P\ 0.001).
The smallest disutilities were for mild anemia (health state
I; difference score = 0.12) and mild rash (L; 0.13), while
Table 3 Utility differences between pairs of health states varying by treatment regimen (N = 182)
Health States Varying by Treatment Regimen
Utility Differences Between Pairs of Health States*
Mean (SD)
A B C D E F G H
A.  All-oral regimen (1 tablet per day) 
0.00 
(0.01) 
0.00 
(0.02) 
0.01 
(0.04) 
0.02 
(0.07) 
0.04 
(0.11) 
0.08 
(0.20) 
0.09 
(0.19) 
B.  All-oral regimen (2 tablets per day) 
0.00 
(0.01) 
0.00 
(0.01) 
0.01 
(0.03) 
0.02 
(0.07) 
0.04 
(0.10) 
0.08 
(0.20) 
0.09 
(0.19) 
C.  All-oral regimen (3 tablets per day) 
0.00 
(0.02) 
0.00 
(0.02) 
0.01 
(0.03) 
0.02 
(0.06) 
0.04 
(0.10) 
0.08 
(0.19) 
0.09 
(0.18) 
D.  All-oral regimen (7 tablets per day) 
0.01 
(0.06) 
0.01 
(0.06) 
0.01 
(0.05) 
0.02 
(0.05) 
0.03 
(0.09) 
0.08 
(0.18) 
0.08 
(0.17) 
E.  Oral treatment (7 tablets per day) + weekly 
injection
0.03 
(0.10) 
0.03 
(0.10) 
0.03 
(0.09) 
0.02 
(0.07) 
0.02 
(0.06) 
0.06 
(0.17) 
0.07 
(0.16) 
F.  Oral treatment (12 tablets per day) + weekly 
injection
0.05 
(0.13) 
0.05 
(0.13) 
0.05 
(0.12) 
0.04 
(0.10) 
0.02 
(0.07) 
0.04 
(0.16) 
0.05 
(0.13) 
G.  Oral treatment (12 tablets per day taken with 
fatty food) + weekly injection 
0.09 
(0.22) 
0.09 
(0.22) 
0.09 
(0.21) 
0.08 
(0.20) 
0.06 
(0.19) 
0.04 
(0.17) 
0.00 
(0.18) 
H.  Oral treatment (18 tablets per day) + weekly 
injection
0.09 
(0.17) 
0.09 
(0.17) 
0.09 
(0.16) 
0.08 
(0.14) 
0.05 
(0.13) 
0.04 
(0.09) 
-0.00 
(0.18) 
* Difference scores above the gray shaded cells were computed with 10-year TTO utility scores. Difference scores below the gray shaded cells
were computed with 1-year TTO utility scores. Difference scores were computed by subtracting health states with letters closer to the end of the
alphabet from health states with letters closer to the beginning of the alphabet (e.g., A–B, A–C, B–C)
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the greatest disutilities were for depression (N; 0.47) and
severe rash (M; 0.48).
Two types of adverse events, rash and anemia, were pre-
sented in separate health states describing mild and severe
conditions. In both cases, the severe adverse event had a
significantly lower utility value than the mild adverse event
(P\ 0.001), with difference scores of 0.35 between mild and
severe rash and 0.20 between mild and severe anemia.
Discussion
Both the 10- and 1-year TTO methods were able to detect
differences in health state preference associated with
treatment regimens and adverse events. More complex and
burdensome treatment regimens, including increased pill
burden, addition of injectable treatment, and a fatty food
requirement, were associated with lower utilities. This
finding adds to the growing body of literature on process
utilities, which quantify the impact of treatment process
characteristics such as mode of administration and dose
frequency [87, 88]. While treatment process is likely to
have less impact on utility than efficacy or safety, the rel-
atively small utility differences associated with treatment
process can influence the outcome of a cost-utility analysis,
particularly when modeling large numbers of patients.
While treatment regimen differences were associated
with utility differences up to 0.09, adverse event disutilities
Table 4 T tests comparing pairs of health states differing in treatment administration attributes (N = 182)
Comparison Hepatitis C health states TTO with 10-year time horizon TTO with 1-year time horizon
Mean
utilitya
Mean (SD)
difference score
P valueb Mean
utilitya
Mean (SD)
difference score
P valueb
A vs B A. 1 tablet per day 0.80 0.00 (0.01) 0.32 0.81 0.00 (0.01) 0.32
B. 2 tablets per day 0.80 0.81
A vs C A. 1 tablet per day 0.80 0.00 (0.02) 0.059 0.81 0.00 (0.02) 0.041
C. 3 tablets per day 0.79 0.80
A vs D A. 1 tablet per day 0.80 0.01 (0.04) 0.0036 0.81 0.01 (0.06) 0.0032
D. 7 tablets per day 0.79 0.79
B vs C B. 2 tablets per day 0.80 0.00 (0.01) 0.045 0.81 0.00 (0.02) 0.071
C. 3 tablets per day 0.79 0.80
B vs D B. 2 tablets per day 0.80 0.01 (0.03) 0.0026 0.81 0.01 (0.06) 0.0043
D. 7 tablets per day 0.79 0.79
C vs D C. 3 tablets per day 0.79 0.01 (0.03) 0.0036 0.80 0.01 (0.05) 0.0068
D. 7 tablets per day 0.79 0.79
D vs E D. 7 tablets per day 0.79 0.02 (0.05) \0.0001 0.79 0.02 (0.07) 0.0002
E. 7 tablets per day ? weekly injection 0.77 0.77
E vs F E. 7 tablets per day ? weekly injection 0.77 0.02 (0.06) 0.0002 0.77 0.02 (0.07) 0.0005
F. 12 tablets per day ? weekly injection 0.75 0.76
E vs H E. 7 tablets per day ? weekly injection 0.77 0.07 (0.16) \0.0001 0.77 0.05 (0.13) \0.0001
H. 18 tablets per day ? weekly injection 0.71 0.72
F vs H F. 12 tablets per day ? weekly injection 0.75 0.05 (0.13) \0.0001 0.76 0.04 (0.09) \0.0001
H. 18 tablets per day ? weekly injection 0.71 0.72
F vs G F. 12 tablets per day ? weekly injection 0.75 0.04 (0.16) 0.0005 0.76 0.04 (0.17) 0.0024
G. 12 tablets per day (taken with fatty
food) ? weekly injection
0.71 0.72
a TTO scores are on a scale anchored with 0 representing dead and 1 representing full health
b P values are based on t tests comparing two utility means
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were larger, ranging from 0.12 to 0.48. Although some of
these disutility values may initially seem larger than
expected, their magnitude is reasonable given the severity
of these adverse events. For example, health state N
describing moderate to severe depression had a utility
value of 0.31, resulting in a disutility of 0.47. Previous
studies of depression utility outside the context of CHC
have found similarly low utility estimates for moderate and
severe depression [89–92]. In the current study, the lowest
rated health state had a mean utility of 0.30, which seems
reasonable given that the health state describes a very
severe rash that can occur as a side effect of treatment with
telaprevir [58, 59, 65].
Studies identifying minimally important differences
(MID) in utility have focused on utilities derived from
generic preference-based measures such as the EQ-5D,
HUI, and SF-6D. For these instruments, MIDs have
generally been reported in a range from 0.01 to 0.08
[93–97]. Less formal estimates of clinically important
differences in direct utility elicitation (e.g., TTO meth-
ods) have suggested thresholds of 0.05–0.10 [38, 98].
Clearly, the disutility of every adverse event examined
in the current study exceeds criteria for an important
utility difference, indicating that it is important to
quantify the impact of these side effects in cost-utility
models. Some of the utility differences among treatment
regimens also exceed MID estimates for utilities
(Table 3).
Because all health states were rated in TTO tasks with
10- and 1-year time horizons, this study offers a unique
opportunity to compare between two time horizons for
multiple health states. Several previous studies have found
that the TTO time horizon can influence results, and dif-
ferent time horizons may lead to different utility scores [61,
99–103]. In the current study, one might expect that the 1-
and 10-year time horizons could generate different
Table 5 T tests comparing pairs of health states differing in adverse events (N = 182)
Comparison Hepatitis C health states TTO with 10-year time horizon TTO with 1-year time horizon
Mean
utilitya
Mean (SD)
difference score
P valueb Mean
utilitya
Mean (SD)
difference score
P valueb
E vs I E. 7 tablets per day plus injectable
medication
0.77 0.12 (0.21) \0.0001 0.77 0.12 (0.23) \0.0001
I. health state E ? mild anemia 0.65 0.65
E vs J E. 7 tablets per day plus injectable
medication
0.77 0.32 (0.33) \0.0001 0.77 0.30 (0.31) \0.0001
J. health state E ? severe anemia 0.45 0.47
E vs K E. 7 tablets per day plus injectable
medication
0.77 0.21 (0.27) \0.0001 0.77 0.20 (0.26) \0.0001
K. health state E ? flu-like
symptoms
0.56 0.57
E vs L E. 7 tablets per day plus injectable
medication
0.77 0.13 (0.26) \0.0001 0.77 0.12 (0.21) \0.0001
L. health state E ? mild rash 0.65 0.66
E vs M E. 7 tablets per day plus injectable
medication
0.77 0.48 (0.44) \0.0001 0.77 0.43 (0.41) \0.0001
M. health state E ? severe rash 0.30 0.34
E vs N E. 7 tablets per day plus injectable
medication
0.77 0.47 (0.42) \0.0001 0.77 0.45 (0.42) \0.0001
N. health state E ? depression 0.31 0.33
L vs M L. health state E ? mild rash 0.65 0.35 (0.38) \0.0001 0.66 0.32 (0.37) \0.0001
M. health state E ? severe rash 0.30 0.34
I vs J I. health state E ? mild anemia 0.65 0.20 (0.26) \0.0001 0.65 0.18 (0.22) \0.0001
J. health state E ? severe anemia 0.45 0.47
a TTO scores are on a scale anchored with 0 representing dead and 1 representing full health
b P values are based on t tests comparing two utility means
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preference scores. For example, some symptoms, adverse
events, or treatment regimens may seem more tolerable for
shorter durations than for longer periods of time. However,
in contrast to previous literature suggesting that different
time horizons may yield different results, the current study
found that 10- and 1-year utility scores were remarkably
similar to each other (Table 2). The consistent results
across time horizons suggest that the health state utilities
were robust and stable, regardless of the time horizon used
in the TTO task. Because the 1-year time horizon more
closely corresponds to a course of hepatitis C treatment
than the 10-year timeframe, researchers may prefer to use
the 1-year values in the base case analysis of a cost-utility
model.
Despite logical results, some study design characteristics
suggest that findings should be interpreted with appropriate
caution. The hypothetical health state approach is limited
by the accuracy and level of detail in the health state
descriptions. In addition, this approach has a potential
focusing effect, which could lead respondents to attend
more closely to small differences among health states. Still,
this method was used because it is well-suited for isolating
utility impact of specific treatment-related attributes, in
contrast to generic measures such as the EQ-5D, which
may not be sensitive to these attributes. However, the
extent to which current utilities would correspond to
patients’ ratings of their own health is not known. If
comparability between current utilities and EQ-5D derived
utilities is important for a particular cost-utility model, it is
recommended that modelers use the utility values derived
in the 10-year TTO assessment, which is consistent with
the methods originally used to value EQ-5D health states
[78].
Another possible limitation is that all health states
explicitly named the disease that was described (i.e.,
‘‘diagnosed with hepatitis C’’). Some studies have sug-
gested that including the disease label in a health state can
influence utility scores, although other studies have reported
situations when the label did not affect valuations [104–
106]. To avoid risk of influencing utility values, some
researchers recommend omitting the disease label from
health states, while others include the label to make the
health state as clear as possible. One advantage of including
the label is that health states with the disease name more
closely represent the patient experience because patients
typically know the name of their condition. In the current
study, it was determined that the health states should
include the label because most patients with hepatitis C are
asymptomatic. Therefore, the label was necessary to
emphasize that each health state described a patient with a
serious medical condition, despite a lack of symptoms.
Two other health state design decisions were also made
because hepatitis C is usually asymptomatic. Whenever
possible, health states should avoid statements involving
uncertainty, which could increase variance and error
because respondents’ interpretations of the uncertain
statements could vary. In addition, it is usually best for
health states to focus on description, without telling the
respondent how to feel about the medical condition, in
order to avoid biasing the responses. However, because
hepatitis C is asymptomatic in most cases, health states for
the current study included long-term risks (e.g., liver
damage) and emotional impact (e.g., fear of future risks) in
order to underscore the potential seriousness of this con-
dition despite the lack of symptoms. While including risks
and emotional impact could lead to error or biased health
state valuations, these statements were identical in all 14
health states. Therefore, these health state characteristics
would not have biased key results, which are the differ-
ences between health state pairs rather than the absolute
value of any individual health state utility.
Two additional limitations of the adverse event health
states should be noted. First, adverse events were all added
to the treatment regimen described in health state E (i.e.,
seven daily tablets plus weekly injection). It is possible that
the adverse event disutilities could be different if the
adverse events were added to health states with different
treatment regimens. However, in the current study, it was
not feasible to add additional health states to an interview
that was already quite complex with 14 health states and
two time horizons. Second, although patients treated for
hepatitis C may experience multiple adverse events, dis-
utility estimates in the current study represent the utility
decrease associated with a single adverse event. Current
results do not provide insight into the utility impact of
multiple simultaneous adverse events.
Despite these limitations, the current study provides
utility scores that may be used in cost-utility modeling to
provide a more detailed representation of experience with
hepatitis C treatment. Both 10- and 1-year TTO method-
ology yielded health state utilities in a reasonable range
with logical discrimination between health states. By using
the current utility scores, models can quantify the impact of
treatment regimen and adverse events when comparing the
value of new and previously available treatments.
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